CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS

Cyclin D1 (CCND1) and retinoblastoma (Rb) genes are cell cycle regulators which are altered in some breast carcinomas. However, the possible cooperation between CCND1 and Rb, as well as the influence and coincidence of their abnormalities in the proliferative capacity of mammary carcinoma cells in vivo, is still unknown. In order to assess both the significance of the CCND1 gene and Rb alterations in breast carcinomas and their relationship with the proliferative capacity of the tumours and other clinico‐pathological factors, CCND1 mRNA expression was studied in 46 cases of primary breast carcinomas and matched normal tissue, 45 of which were also studied immunohistochemically. Rb expression was analysed in the same cases by immunohistochemistry, whereas the proliferative activity of the carcinomas was evaluated by flow cytometry. CCND1 mRNA was overexpressed in 19 tumours (41 per cent). Sixteen cases showed diffuse immunohistochemical expression, ten carcinomas had few positive cells, and 19 were absolutely negative. CCND1 mRNA and protein overexpression was associated with oestrogen receptor (ER) expression by the tumour. Interestingly, lack of ER expression was associated with a decreased CCND1 mRNA signal in non‐overexpressed tumours. No association was observed between CCND1 mRNA or protein overexpression and tumour proliferation or other clinico‐pathological parameters. Loss of Rb expression was observed in 26 per cent of the tumours. This abnormality was significantly associated with increased mean S‐phase (P=0·017) and decreased CCND1 mRNA expression in non‐overexpressed tumours, supporting in vivo the postulated regulatory loop between Rb and CCND1 in vitro. We conclude that CCND1 up‐regulation is not associated with increased proliferative activity in breast carcinomas, whereas its expression might be regulated in vivo by hormones and Rb. Loss of Rb expression is significantly associated with an increased proliferation of tumour cells, suggesting an important role in the progression of a subset of breast carcinomas, regardless of CCND1 abnormalities. © 1997 John Wiley & Sons, Ltd.

[1]  B. Jennings,et al.  Cyclin D1 amplification and expression in human breast carcinoma: correlation with histological prognostic markers and oestrogen receptor expression , 1996, Clinical molecular pathology.

[2]  B. Angus,et al.  Determination of the prognostic value of cyclin D1 overexpression in breast cancer. , 1995, Oncogene.

[3]  E. Schmidt,et al.  Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[4]  J. Foekens,et al.  Association between rb‐1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival , 1995, International journal of cancer.

[5]  J. Bartek,et al.  Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. , 1995, Cancer letters.

[6]  J. Bartek,et al.  Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. , 1995, Oncogene.

[7]  V. Kosma,et al.  Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. , 1995, European journal of cancer.

[8]  Jun-yan Hong,et al.  Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric‐cardia carcinogenesis , 1994, International journal of cancer.

[9]  A. Klein-Szanto,et al.  Immunohistochemistry of cyclin D1 in human breast cancer. , 1994, American journal of clinical pathology.

[10]  R. Chaganti,et al.  TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines , 1994, International journal of cancer.

[11]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma , 1994 .

[12]  F. Bosch,et al.  PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. , 1994, Cancer research.

[13]  R. Sclafani,et al.  Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Benedict,et al.  Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti‐RB antibodies , 1994, International journal of cancer.

[15]  A. El‐Naggar,et al.  PRAD‐1 (CCND1)/Cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma , 1994, Cancer.

[16]  Emma Lees,et al.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice , 1994, Nature.

[17]  L. Bonetta,et al.  Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. , 1994, Oncogene.

[18]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[19]  J. Bartek,et al.  DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 , 1994, The Journal of cell biology.

[20]  J. Bartek,et al.  Cyclin D1 expression is regulated by the retinoblastoma protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Bartek,et al.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.

[22]  J. Bartek,et al.  Cell cycle‐related variation and tissue‐restricted expression of human cyclin D1 protein , 1994, The Journal of pathology.

[23]  R. Weinberg,et al.  Function of a human cyclin gene as an oncogene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Sonenberg,et al.  Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E , 1993, Molecular and cellular biology.

[25]  R. Sutherland,et al.  Cyclin gene expression and growth control in normal and neoplastic human breast epithelium , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  H. Sakamoto,et al.  Amplification and overexpression of EXP1 and EXP2/Cyclin D1 genes in human esophageal carcinomas. , 1993, Biochemical and biophysical research communications.

[27]  C. J. Chen,et al.  Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.

[28]  C. Harris,et al.  Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. A. Hamilton,et al.  Expression and amplification of cyclin genes in human breast cancer. , 1993, Oncogene.

[30]  S. Shurtleff,et al.  Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. , 1993, Genes & development.

[31]  J. A. Hamilton,et al.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. , 1993, Molecular and cellular biology.

[32]  R. Weinberg,et al.  Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.

[33]  M. Ewen,et al.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. , 1993, Genes & development.

[34]  K. Keyomarsi,et al.  Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Cavenee,et al.  Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. , 1992, Human pathology.

[36]  M. J. van de Vijver,et al.  Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. , 1992, Cancer research.

[37]  B. Angus,et al.  Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study , 1992, The Journal of pathology.

[38]  N. Harris,et al.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[39]  O. Melnyk,et al.  Characterization of a candidate bcl-1 gene , 1991, Molecular and cellular biology.

[40]  B. Futcher,et al.  Human D-type cyclin , 1991, Cell.

[41]  A. Arnold,et al.  A novel cyclin encoded by a bcl1-linked candidate oncogene , 1991, Nature.

[42]  M. Fernö,et al.  Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. , 1991, British Journal of Cancer.

[43]  R. Figlin,et al.  Frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. The Lung Cancer Study Group. , 1990, Oncogene.

[44]  G. Peters,et al.  Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. , 1990, European journal of cancer.

[45]  I. Ellis,et al.  Pathology and breast screening , 1990, Histopathology.

[46]  D. Birnbaum,et al.  BCL-1 participates in the 11q13 amplification found in breast cancer. , 1990, Oncogene.

[47]  Y. Fujiwara,et al.  Mechanisms of estrogen action on the proliferation of MCF-7 human breast cancer cells in an improved culture medium. , 1989, Cancer research.

[48]  C. Theillet,et al.  Proto-oncogene amplification and human breast tumor phenotype. , 1989, Oncogene.

[49]  R. Eddy,et al.  Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. , 1989, The Journal of clinical investigation.

[50]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[51]  G. Merlo,et al.  The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. , 1989, Oncogene.

[52]  R. Clarke,et al.  Regulation of breast cancer cells by hormones and growth factors: effects on proliferation and basement membrane invasiveness. , 1989, Hormone research.

[53]  J. Varley,et al.  Structural rearrangement of the retinoblastoma gene in human breast carcinoma. , 1988, Science.

[54]  W. Lee,et al.  Inactivation of the retinoblastoma susceptibility gene in human breast cancers. , 1988, Science.

[55]  B. Leung,et al.  Mode of estrogen action on cell proliferation in CAMA‐1 cells: II. Sensitivity of G1 phase population , 1987, Journal of cellular biochemistry.

[56]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[57]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[58]  M. Lippman,et al.  Oestrogen-responsive human breast cancer in long term tissue culture , 1975, Nature.